Investigational drug · Phase 2
Teverelix DP
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Teverelix DP"
First trial start
2026
Jul 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Teverelix DP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Urinary Retention
- Benign Prostate Hypertrophy(BPH)
- Endometriosis Pelvic
- Endometriosis Ovaries
- Premenopausal
- Endometriosis (Diagnosis)
- Dysmenorrhoea
- Dyspareunia (Female)
- Advanced Prostate Cancer
- GnRH Antagonist
Approved drugs for the same conditions: Prostate cancer · Endometriosis · Oncology · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Teverelix DP" as an intervention, largest first.
- Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary RetentionPivotal-lookingNot yet recruiting
Antev Ltd.Industry
NCT07733934 · 126 participants (planned) · Start Jan 2027 · Primary completion May 2028
Drug: Teverelix DP; Teverelix DP Placebo and 2 more · For: Acute Urinary Retention; Benign Prostate Hypertrophy(BPH)
- PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine CorrelatesNot yet recruiting
Antev Ltd.Industry
NCT07914062 · 84 participants (planned) · Start Feb 2027 · Primary completion Dec 2029
Drug: Teverelix DP; Teverelix DP and 2 more · For: Endometriosis Pelvic; Endometriosis Ovaries; Premenopausal and 3 more
Antev Ltd.Industry
NCT07457164 · 40 participants (planned) · Start Jul 2026 · Primary completion Sep 2027
Drug: Teverelix DP 180 mg · For: Advanced Prostate Cancer; GnRH Antagonist
Newest research
PubMed records naming it or its code names, newest first.
- A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk.
Sannala CKR, MacLean C, Larsen F, et al. · Clin Pharmacol Drug Dev 2024
- Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
Ulys A, Jankevicus F, Jievaltas M, et al. · Prostate 2024
- Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies.
MacLean CM, Ulys A, Jankevičius F, et al. · Medicina (Kaunas) 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.